A Phase 2b/3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects with Acute Traumatic Cervical Spinal Cord Injury
ID Number 16-0372Principal Investigator(s)
Arthur L Jenkins III
Department(s) or Division(s)
The purpose of this study is to assess the efficacy and safety of the VX-210 study drug in patient with acute traumatic cervical spinal cord injury with AIS class A or B. The drug is given to the patients during standard of care procedures within 72 hours of initial injury.
Recruiting Patients: Yes